Zacks Research Issues Positive Outlook for Omnicell Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Equities research analysts at Zacks Research lifted their Q1 2025 earnings estimates for shares of Omnicell in a research report issued to clients and investors on Thursday, November 14th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.15 for the quarter, up from their prior forecast of $0.14. The consensus estimate for Omnicell’s current full-year earnings is $0.74 per share. Zacks Research also issued estimates for Omnicell’s Q2 2025 earnings at $0.18 EPS.

OMCL has been the topic of a number of other reports. Barclays lifted their price target on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Benchmark reaffirmed a “buy” rating and issued a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Craig Hallum increased their price target on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company raised their price target on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Finally, Bank of America reaffirmed a “neutral” rating and set a $57.00 price objective (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $50.83.

Omnicell Stock Performance

OMCL stock opened at $42.41 on Monday. The company’s fifty day moving average price is $44.23 and its 200-day moving average price is $37.08. Omnicell has a one year low of $25.12 and a one year high of $55.74. The company has a market capitalization of $1.96 billion, a PE ratio of -108.74, a price-to-earnings-growth ratio of 43.97 and a beta of 0.81.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its stake in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Omnicell by 248.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares during the period. 1620 Investment Advisors Inc. lifted its position in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after buying an additional 1,542 shares during the last quarter. EntryPoint Capital LLC boosted its stake in Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after buying an additional 1,345 shares during the period. Finally, CWM LLC increased its position in Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after acquiring an additional 1,236 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.